Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2006-06-13
2006-06-13
O'Hara, Eileen (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S085100, C424S145100, C514S008100, C514S012200, C514S893000
Reexamination Certificate
active
07060262
ABSTRACT:
Immune stimulatory amounts of hematopoietic colony stimulating factors are administered to patients with inflammatory bowel disease. The factors include G-CSF and GM-CSF. These factors induce and maintain remission of the disease and its manifestations, whether within the intestine or without.
REFERENCES:
patent: 4961926 (1990-10-01), Gabrilove
patent: 5284656 (1994-02-01), Platz et al.
patent: 5468846 (1995-11-01), Ichikawa et al.
patent: 5606024 (1997-02-01), Boone et al.
patent: 5654186 (1997-08-01), Cerami
patent: 5762920 (1998-06-01), Yung et al.
patent: 5767156 (1998-06-01), Ferrante et al.
patent: 5790421 (1998-08-01), Osslund
patent: 5814308 (1998-09-01), Zhang
patent: 6020469 (2000-02-01), Hershenson
patent: 6037324 (2000-03-01), Schwender et al.
patent: WO 00 06080 (2000-02-01), None
patent: WO 00 47195 (2000-08-01), None
Roe et al. Brief Report: treatment of Chronic Inflammation Bowel Disease in Glycogen Storage Disease Type lb with Colony Stimulating Factors. The New England Journal of Medicine, vol. 326, No. 25, pp. 1666-1992.
B. Drumm et al., “Granulocyte-macrophage colony-stimulating factor for Crohn's disease”,The Lancet, (May 24, 2003) vol. 361, pp. 1830-1831.
B. Dieckgraefe et al. “Authors Reply”,The Lancet, (May 24, 2003) vol. 361, pp. 1830-1831.
D. Vaughn et al., “Treatment of Fistulas with Granulocyte Colony-Stimulating Factor in a Patient with Crohn's Disease”,N.E.J.M.(1999) vol. 340, pp. 239-240.
J. R. Korzenik et al., “Immunostimulation in Crohn's disease: Results of a pilot study of G-CSF (R-MethuG-SCF) in mucosal and fistulizing Crohn's disease”,Gastroenterology, (Apr. 2000) vol. 118, No. 4, Suppl. 2, part 1, pp. A874-A875 Abstract nr 4852.
J.R. Korzenik et al., “Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease”,Digestive Diseases and Sciences(Jun. 2000) vol. 45, No. 6, pp. 1121-1129.
C.J. Bagley et al., “The structural and functional basis of cytokine receptor activation: Lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors”,Blood, (Mar. 1, 1997), vol. 89, No. 5, pp. 1471-1482.
J. R. Korzenik et al., “Immune stimulation in Crohn's disease: Safety and efficacy of rbuGM-CSF for the treatment of active Crohn's disease”Gastroenterology, (Apr. 2001) vol. 120, No. 5, Suppl. 1, pp. A277-278 Abstract nr. 1437.
R. Leake, “Molecular Aspects of the GM-CSF Receptor: An Example of the Cell Signalling Mechanism Used by Type 1 Cytokine Receptors”, European Journal of Cancer, vol. 35, Supp. 3, pp. S2-S3, 1999.
Roe et al. “Treatment of Chronic Inflammatory Disease in Glycogen Storage Disease Type 1 b with GM-CSF,”The New England Journal of Medicine, (1992), pp. 1666-1669, vol. 326, No. 25.
Dieckgraefe Brian K.
Korzenik Joshua
Banner & Witcoff , Ltd.
Hamud Fozia
O'Hara Eileen
The Washington University
LandOfFree
Stimulating neutrophil function to treat inflammatory bowel... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stimulating neutrophil function to treat inflammatory bowel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stimulating neutrophil function to treat inflammatory bowel... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3665296